WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) today announced that multiple studies were presented at the 2019 European Association of Urology (EAU) meeting in Barcelona, Spain, highlighting the effectiveness of the UroLift System, a minimally invasive treatment, usually performed in-office that provides rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH).1,2
BPH, also known as enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.3BPH affects over 40 million men in the United States alone.4If left untreated, the condition can worsen over time and cause permanent bladder damage.5
A presentation entitled Pulling The Foley: Can the Prostatic Urethral Lift be used in men with catheter-dependent urinary retention? was presented by Thomas Mueller, M.D., urologist of New Jersey Urology (Voorhees, N.J.). The study highlighted real-world retrospective data from a study of 30 men with urinary retention treated with the UroLift System.
Since a significant number of men with BPH also have urinary retention that requires a catheter, Dr. Muellers objective for the study was to determine whether the ...